Literature DB >> 12958234

Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study.

Mónica V Cunha1, Jorge H Leitão, Eshwar Mahenthiralingam, Peter Vandamme, Luís Lito, Celeste Barreto, Maria José Salgado, Isabel Sá-Correia.   

Abstract

This work reports results of a systematic molecular analysis involving 113 Burkholderia cepacia complex isolates obtained from 23 cystic fibrosis (CF) patients under surveillance over a 7-year period at the major Portuguese CF center, the Santa Maria Hospital in Lisbon. The majority of the isolates were serial isolates from persistently infected patients (more than one-half of the population examined). In agreement with previous studies, B. cenocepacia (formerly genomovar III) was the most prevalent species; it was isolated from 52% of the patients infected with B. cepacia complex isolates. Contrasting with previous studies, a very significant percentage of the Portuguese CF subpopulation examined was infected with B. cepacia genomovar I (36%) and B. stabilis (18%). B. multivorans was recovered from two of the infected patients. All four of the species or genomovars were associated with poor clinical outcome, including the cepacia syndrome, and gave rise to chronic and transient infections, with the clinical condition depending on the patient and other still-unidentified factors. The B. cepacia epidemic strain marker region was found exclusively in genomovar III strains, while cblA was detected in genomovars I and III, only. There was no clear relation between the presence of these markers and transmissibility. Altogether, our results indicate that the use of these markers or the genomovar status in identifying patients at higher risk for infection is uncertain.

Entities:  

Mesh:

Year:  2003        PMID: 12958234      PMCID: PMC193798          DOI: 10.1128/JCM.41.9.4113-4120.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.

Authors:  J R Govan; P H Brown; J Maddison; C J Doherty; J W Nelson; M Dodd; A P Greening; A K Webb
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

2.  Molecular typing and exopolysaccharide biosynthesis of Burkholderia cepacia isolates from a Portuguese cystic fibrosis center.

Authors:  J A Richau; J H Leitão; M Correia; L Lito; M J Salgado; C Barreto; P Cescutti; I Sá-Correia
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom.

Authors:  F E Clode; M E Kaufmann; H Malnick; T L Pitt
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis.

Authors:  Tom Coenye; John J LiPuma
Journal:  J Infect Dis       Date:  2002-04-23       Impact factor: 5.226

5.  Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV).

Authors:  P Vandamme; E Mahenthiralingam; B Holmes; T Coenye; B Hoste; P De Vos; D Henry; D P Speert
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

6.  Burkholderia cenocepacia sp. nov.--a new twist to an old story.

Authors:  Peter Vandamme; Barry Holmes; Tom Coenye; Johan Goris; Eshwar Mahenthiralingam; John J LiPuma; John R W Govan
Journal:  Res Microbiol       Date:  2003-03       Impact factor: 3.992

7.  Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.

Authors:  D L Smith; L B Gumery; E G Smith; D E Stableforth; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

Review 8.  Burkholderia cepacia complex infection in patients with cystic fibrosis.

Authors:  Eshwar Mahenthiralingam; Adam Baldwin; Peter Vandamme
Journal:  J Med Microbiol       Date:  2002-07       Impact factor: 2.472

9.  Evaluation of species-specific recA-based PCR tests for genomovar level identification within the Burkholderia cepacia complex.

Authors:  Karen Vermis; Tom Coenye; Eshwar Mahenthiralingam; Hans J Nelis; Peter Vandamme
Journal:  J Med Microbiol       Date:  2002-11       Impact factor: 2.472

10.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  37 in total

1.  Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Kathleen M Thickett; David Honeybourne; Martin C J Maiden; John R Govan; David P Speert; John J Lipuma; Peter Vandamme; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

2.  Functional analysis of Burkholderia cepacia genes bceD and bceF, encoding a phosphotyrosine phosphatase and a tyrosine autokinase, respectively: role in exopolysaccharide biosynthesis and biofilm formation.

Authors:  Ana S Ferreira; Jorge H Leitão; Sílvia A Sousa; Ana M Cosme; Isabel Sá-Correia; Leonilde M Moreira
Journal:  Appl Environ Microbiol       Date:  2006-11-17       Impact factor: 4.792

3.  Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center.

Authors:  Mónica V Cunha; Ana Pinto-de-Oliveira; Luís Meirinhos-Soares; Maria José Salgado; José Melo-Cristino; Susana Correia; Celeste Barreto; Isabel Sá-Correia
Journal:  J Clin Microbiol       Date:  2007-03-14       Impact factor: 5.948

4.  SNaPBceBcon: a Practical Tool for Identification and Genotyping of Burkholderia cepacia and Burkholderia contaminans.

Authors:  Ricardo Araujo; Rita Caramalho; Carla Coutinho; Isabel Sá-Correia
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

5.  Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Authors:  S Campana; G Taccetti; N Ravenni; F Favari; L Cariani; A Sciacca; D Savoia; A Collura; E Fiscarelli; G De Intinis; M Busetti; A Cipolloni; A d'Aprile; E Provenzano; I Collebrusco; P Frontini; G Stassi; M Trancassini; D Tovagliari; A Lavitola; C J Doherty; T Coenye; J R W Govan; P Vandamme
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 6.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

7.  The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.

Authors:  Ana S Ferreira; Inês N Silva; Fábio Fernandes; Ruth Pilkington; Máire Callaghan; Siobhán McClean; Leonilde M Moreira
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

8.  Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections.

Authors:  Mónica V Cunha; Sílvia A Sousa; Jorge H Leitão; Leonilde M Moreira; Paula A Videira; Isabel Sá-Correia
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 9.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

10.  Environmental Burkholderia cepacia complex isolates in human infections.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Pavel Drevinek; Peter Vandamme; John R Govan; David J Waine; John J LiPuma; Luigi Chiarini; Claudia Dalmastri; Deborah A Henry; David P Speert; David Honeybourne; Martin C J Maiden; Chris G Dowson
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.